XOMA (US) LLC clinical trials
Acquired by Ligand Pharmaceuticals Incorporated, Jul 14, 2026 · source ↗
The registry lists 25 studies whose lead sponsor is XOMA (US) LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 21, 2021.
Before and after it joined Ligand Pharmaceuticals Incorporated
- First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- 25
- First submitted after XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- XOMA (US) LLC25 studies
Something wrong with this grouping? Tell us on the Ligand Pharmaceuticals Incorporated page.
Studies
Recruiting first, then most recently updated. Showing 25 of 25. All Ligand Pharmaceuticals Incorporated studies →
- An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass SurgeryCompletedNCT02772718Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital HyperinsulinismCompletedNCT02604485Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic TreatmentTerminatedNCT01747538Phase 3
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02326740Phase 3
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02315417Phase 3
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedNCT02318914Phase 3
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious UveitisTerminatedNCT01684345Phase 3
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear DiseaseCompletedNCT01950312Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedNCT01882504Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease UveitisTerminatedNCT02258867Phase 3
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid ArthritisSuspendedNCT00777816Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety DataTerminatedNCT02258854Phase 3
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the HandCompletedNCT02293564Not applicable
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne VulgarisCompletedNCT01498874Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the HandCompletedNCT01882491Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the HandCompletedNCT01683396Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 DiabetesCompletedNCT00998699Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)TerminatedNCT00454155Phase 1/2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes MellitusCompletedNCT01144975Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes MellitusCompletedNCT00513214Phase 1/2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin MonotherapyCompletedNCT01066715Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes MellitusCompletedNCT00541983Phase 1
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic ArthritisCompletedNCT00051662Phase 1
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Phase I Study of a Monoclonal Antibody for Treatment of Advanced AdenocarcinomasCompletedNCT00051675Phase 1
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated
- Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.CompletedNCT00034203Phase 2
Sponsor listed in the registry: XOMA (US) LLC · First submitted before XOMA (US) LLC became part of Ligand Pharmaceuticals Incorporated